$271.90
At close: May 22 EDT
$271.68
-0.22-0.08%
Pre-Market: 7:20 PM EDT
Comments
Loading...
Latest Amgen Stock News | NASDAQ:AMGN | Benzinga
Get the latest news on Amgen stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Amgen performance
Categories: All
Tuesday, May 20, 2025
Friday, May 16, 2025
Thursday, May 15, 2025
Wednesday, May 14, 2025
Monday, May 12, 2025
Wednesday, May 07, 2025
- What the Options Market Tells Us About Amgen
- MHRA Approves Teprotumumab As The First UK Tr...
- VP Of Amgen Sold $279K In Stock
- Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
- Forecasting The Future: 7 Analyst Projections For Amgen
- Mizuho Maintains Neutral on Amgen, Raises Pri...
Friday, May 02, 2025
- UBS Maintains Neutral on Amgen, Lowers Price ...
- Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
- RBC Capital Maintains Outperform on Amgen, Lo...
- Nasdaq 100 Leads Wall Street Rally As China Signals Openness To Fentanyl Talks, Easing Trade Tensions
- Wall Street Eyes 9th Straight Day Of Gains, Apple Falls As Chinese Sales Disappoint: What's Driving Markets Friday?
- Amgen Unusual Options Activity For May 02
Thursday, May 01, 2025
- Amgen Affirms FY2025 Adj EPS Guidance of $20....
- Amgen Raises FY2025 GAAP EPS Guidance from $1...
- Amgen Q1 Adj. EPS $4.90 Beats $4.30 Estimate,...
- Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday? (CORRECTED)
- Earnings Scheduled For May 1, 2025
Wednesday, April 30, 2025
Friday, April 25, 2025
Wednesday, April 23, 2025
Tuesday, April 22, 2025
Monday, April 21, 2025
Thursday, April 17, 2025
Monday, April 14, 2025
Friday, April 11, 2025
Wednesday, April 09, 2025
Monday, April 07, 2025
Friday, April 04, 2025
- Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
- Nasdaq 100 Enters Bear Market, Dow In Correction Territory, Traders Await Fed Chair Powell's Remarks
- FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder
- Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades'
